McKesson Corporation has decided to divest from their Canada-based businesses,
Rexall and
Well.ca, in an effort to concentrate on their growth within the
Oncology and
Biopharma sectors. This strategic sale however, led to a slump in the company's stock.
Leann Smith, the chief HR officer of McKesson, sold shares valued at $331,645 right before the company declared its third quarter fiscal 2025 earnings release date. Financial experts, including Jim Cramer, have given conflicting advice about investing in McKesson, with some advocating for the stock's long-term value. Five years ago, investing in the company would have yielded a 333% gain. McKesson Corporation has reported record revenue and strategic growth in Q2 2025. The company managed to raise its
Full-Year EPS Guidance after surpassing Q2 earnings expectations. Despite analysts labeling it as a value stock, their revenue has been negatively affected by supply and demand issues for weight-loss drugs.
Mckesson Corporation MCK News Analytics from Tue, 07 May 2024 07:00:00 GMT to Fri, 03 Jan 2025 21:57:15 GMT -
Rating 3
- Innovation 2
- Information 7
- Rumor -2
